Background and Purpose: Whereas biased agonism on the 5‐HT2A receptor has been ascribed to hallucinogenic properties of psychedelics, no information about biased inverse agonism on this receptor is available. In schizophrenia, increased 5‐HT2A receptor constitutive activity has been suggested, highlighting the therapeutic relevance of inverse agonism. This study characterized the modulation of G protein activity promoted by different drugs, commonly considered as 5‐HT2A receptor antagonists, in post‐mortem human brain cortex.Experimental Approach: Modulation of [35S]GTPγS binding to different subtypes of Gα proteins exerted by different 5‐HT2A receptor drugs was determined by scintillation proximity assays in brain from human, WT and 5‐HT2A receptor KO mice.Key Results: MDL‐11,939 was the only drug having no effect on the basal activity of 5‐HT2A receptor. Altanserin and pimavanserin decreased basal activation of Gi1, but not Gq/11 proteins. This effect was blocked by MDL‐11,939 and absent in 5‐HT2A receptor KO mice. Volinanserin showed 5‐HT2A receptor‐mediated inverse agonism both on Gi1 and Gq/11 proteins. Ketanserin exhibited 5‐HT2A receptor partial agonism exclusively on Gq/11 proteins. On the other hand, eplivanserin and nelotanserin displayed inverse agonism on Gq/11 and/or Gi1 proteins, which was insensitive to MDL‐11,939 and was present in KO mice suggesting a role for another receptor.Conclusion and Implications: The results reveal the existence of constitutively active 5‐HT2A receptors in human pre‐frontal cortex and demonstrate different pharmacological profiles of various 5‐HT2A receptor drugs previously considered antagonists. These findings indicate that altanserin and pimavanserin possess biased inverse agonist profile towards 5‐HT2A receptor activation of Gi1 proteins.LINKED ARTICLES: This article is part of a themed issue Complexity of GPCR Modulation and Signaling (ERNST). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.14/issuetoc
Post-stroke mood disorders (PSMD) affect disease prognosis in adults. Adult rodent models underlie the importance of the dopamine (DA) system in PSMD pathophysiology. There are no studies on PSMD after neonatal stroke. We induced neonatal stroke in 7-day-old (P7) rats by temporal left middle cerebral artery occlusion (MCAO). Performance in the tail suspension test (TST) at P14 and the forced swimming test (FST) and open field test (OFT) at P37 were studied to assess PSMD. DA neuron density in the ventral tegmental area, brain DA concentration and DA transporter (DAT) expression as well as D2 receptor (D2R) expression and G-protein functional coupling were also studied. MCAO animals revealed depressive-like symptoms at P14 associated with decreased DA concentration and reduced DA neuron population and DAT expression. At P37, MCAO rats showed hyperactive behavior associated with increased DA concentration, normalization of DA neuron density and decreased DAT expression. MCAO did not modify D2R expression but reduced D2R functionality at P37. MCAO-induced depressive-like symptoms were reversed by the DA reuptake inhibitor GBR-12909. In conclusion, MCAO in newborn rats induced depressive-like symptoms and hyperactive behavior in the medium and long term, respectively, that were associated with alterations in the DA system.
Antipsychotic activity of certain 5-HT2A receptor (5-HT2AR) antagonists has been attributed to inverse agonism. 5-HT2AR hallucinogenic agonists exhibit biased agonism toward Gi/o proteins. Ketanserin and altanserin are 2 structurally similar orthosteric drugs used as 5-HT2AR therapeutic and radiotracers tools. This study assessed the pharmacological properties of ketanserin and altanserin, previously described as neutral 5-HT2AR antagonists, using postmortem human prefrontal cortex. Receptor radioligand binding experiments and functional [35S]GTPγS (sulfur 35 labeled guanosine-5'-O-[gamma-thio]-triphosphate) binding assays followed by immunocapture with anti-Gαq/11 and anti-Gαi1 protein antibodies were performed. Molecular dynamics simulations were used to ascertain binding modes to the 5-HT2AR. [3H]Ketanserin binding to 5-HT2ARs was decreased by guanylyl-5'-imido-diphosphate, a GTP analog. Guanylyl-5'-imido-diphosphate transformed the biphasic inhibition of [3H]ketanserin binding by the agonist (±)DOI into a monophasic low-affinity curve. Ketanserin stimulated [35S]GTPγS binding to Gαq/11 but not Gαi1 proteins. Conversely, altanserin inhibited [35S]GTPγS binding to Gαi1 but not Gαq/11 proteins. These effects were blocked by the neutral antagonist MDL-11,939. Altanserin-induced inhibition was abolished by the Gαi/o alkylating agent N-ethylmaleimide. Similar findings were observed in wild type but disappeared in 5-HT2AR knockout mice. Ketanserin and altanserin showed distinct interactions within residues S2.61, S5.46, and N6.55 in the 5-HT2AR binding pocket. Therefore, ketanserin and altanserin elicit biased signaling with different patterns of G protein modulation upon interacting with 5-HT2ARs in brain. Ketanserin behaves as partial agonist on Gq/11, whereas altanserin acts as inverse agonist on Gi1 proteins. These findings should influence the design of antipsychotic drugs targeting this receptor and when used as antagonists and radiotracers for the 5-HT2AR assessment. SIGNIFICANCE STATEMENT: Ketanserin and altanserin are categorized as neutral 5-HT2A receptor antagonists. This study shows differential patterns of 5-HT2A receptor coupling to Gαq/11 and Gαi1 proteins between ketanserin and altanserin and demonstrates biased signaling and inverse agonism in human brain.